High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant

American Journal of Transplantation

Volumn 11, Issue 9, 2011, Pages 1868-1876

  O'Leary, J G ^a   Kaneku, H ^b   Susskind, B M ^a   Jennings, L W ^a   Neri, M A ^a   Davis, G L ^a   Klintmalm, G B ^a   Terasaki, P I ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b TERASAKI FOUNDATION LABORATORY   (United States)

Author keywords

Chronic allograft rejection; donor specific antibodies; HLA antibodies; Liver Transplantation

Indexed keywords

ANTIBODY; DONOR SPECIFIC ANTIBODY; HLA ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY SPECIFICITY; ARTICLE; CHRONIC GRAFT REJECTION; FEMALE; FLUORESCENCE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETRANSPLANTATION; SURVIVAL TIME;

ADULT; AUTOANTIBODIES; FEMALE; FLUORESCENCE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; TISSUE DONORS;

EID: 80052261583     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03593.x     Document Type: Article

References (23)

1. Gordon RD, Fung JJ, Markus B, et al,. The antibody crossmatch in liver transplantation. Surgery 1986; 100: 705-715. (Pubitemid 16008843)
2. Moore SB, Wiesner RH, Perkins JD, Nagorney DM, Sterioff S, Krom RA,. A positive lymphocyte cross-match and major histocompatibility complex mismatching do not predict early rejection of liver transplants in patients treated with cyclosporine. Transplant Proc 1987; 19 (Pt 3): 2390-2391.
3. Ogura K, Koyama H, Takemoto S, Terasaki PI, Busuttil RW,. Significance of a positive crossmatch on outcome in human liver transplantation. Transplant Proc 1992; 24: 1465.
4. Ogura K, Terasaki PI, Koyama H, Chia J, Imagawa DK, Busuttil RW,. High one-month liver graft failure rates in flow cytometry crossmatch-positive recipients. Clin Transplant 1994; 8 (Pt 1): 111-115. (Pubitemid 24105401)
5. Takaya S, Duquesnoy R, Iwaki Y, et al., Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc 1991; 23 (Pt 1): 396-399.
6. Castillo-Rama M, Castro MJ, Bernardo I, et al,. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: Role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554-562. (Pubitemid 351524413)
7. Goh A, Scalamogna M, De Feo T, Poli F, Terasaki PI,. Human leukocyte antigen crossmatch testing is important for liver retransplantation. Liver Transpl 2010; 16: 308-313.
8. Kasahara M, Kiuchi T, Takakura K, et al,. Postoperative flow cytometry crossmatch in living donor liver transplantation: Clinical significance of humoral immunity in acute rejection. Transplantation 1999; 67: 568-575. (Pubitemid 29114220)
9. Fontana M, Moradpour D, Aubert V, Pantaleo G, Pascual M,. Prevalence of anti-HLA antibodies after liver transplantation. Transpl Int 2010; 23: 858-859.
10. Demetris AJ, Markus BH, Burnham J, et al,. Antibody deposition in liver allografts with chronic rejection. Transplant Proc 1987; 19 (Suppl 5): 121-125. (Pubitemid 17151787)
11. Demetris A, Adams D, Bellamy C, et al,. Update of the international banff schema for liver allograft rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection. An Int Panel Hepatol 2000; 31: 792-799. (Pubitemid 30118655)
12. Mizutani K, Terasaki P, Hamdani E, et al,. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007; 7: 1027-1031. (Pubitemid 46481199)
13. Batal I, Zeevi A, Lunz JG 3rd, et al,. Antihuman leukocyte antigen-specific antibody strength determined by complement-dependent or solid-phase assays can predict positive donor-specific crossmatches. Arch Pathol Lab Med 2010; 134: 1534-1540.
14. Singh N, Djamali A, Lorentzen D, et al,. Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant. Outcomes Transplant 2010; 90: 1079-1084.
15. Agarwal A, Dar W, Watkins C, et al,. Donor-directed MHC class I antibody is preferentially cleared in sensitized recipients of combined liver/kidney transplants. Am J Transplant 2011; 11: 841-847.
16. Lee PC, Zhu L, Terasaki PI, Everly MJ,. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88: 568-574.
17. Hove WR, van Hoek B, Bajema IM, Ringers J, van Krieken JH, Lagaaij EL,. Extensive chimerism in liver transplants: Vascular endothelium, bile duct epithelium, and hepatocytes. Liver Transpl 2003; 9 552-556. (Pubitemid 36701689)
18. Ruiz R, Tomiyama K, Chinnakotla S, et al,. The positive crossmatch in liver transplantation: A risk factor for preservation injury? XXIII Int Cong Transplant Soc. 2010: Abstract 060.07.
19. Kozlowski T, Rubinas T, Nickeleit V, et al,. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl. 2011; 17: 357-368.
20. Cruse J, Lewis R, Wang H,. Immunology guidebook. San Diego: Elsevier Academic Press; 2004.
21. Zachary AA, Montgomery RA, Leffell MS,. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005; 66: 364-370. (Pubitemid 40615791)
22. Zachary AA, Leffell MS,. Detecting and monitoring human leukocyte antigen-specific antibodies. Hum Immunol 2008; 69: 591-604.
23. Moonka DK, Kim D, Kapke A, Brown KA, Yoshida A,. The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation. Am J Transplant 2010; 10: 590-601.